Equities

SSY Group Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

SSY Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.02
  • Today's Change-0.01 / -0.33%
  • Shares traded415.21k
  • 1 Year change-7.93%
  • Beta0.5535
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

  • Revenue in HKD (TTM)4.58bn
  • Net income in HKD658.92m
  • Incorporated2004
  • Employees5.70k
  • Location
    SSY Group LtdRooms 4902-03, 49th Floor, Central Plaza18 Harbour RoadWanchai Hong KongHKG
  • Phone+852 26880869
  • Fax+852 27873338
  • Websitehttps://www.ssygroup.com.hk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shandong Boan Biotechnology Co Ltd856.16m36.24m4.73bn714.00119.561.9035.895.520.06360.06361.514.000.25301.341.731,053,085.001.07--1.41--71.70--4.23--1.451.810.2827--17.50--161.31------
VIVA Biotech Holdings2.08bn194.91m4.90bn2.09k32.481.109.752.360.07080.07080.68082.090.26124.244.941,007,213.003.22-1.283.81-1.5637.4434.3012.33-4.941.44--0.2283---7.8443.80244.08-8.8527.82--
Beijing Luzhu Biotechnology Co Ltd0.00-153.71m5.17bn197.00--6.24-----0.7658-0.76580.004.170.00----0.00-12.48---13.69----------4.68--0.2296------32.53------
Tong Ren Tang Technologies Co Ltd7.86bn488.40m5.66bn3.89k11.590.68584.580.72020.38130.38136.146.440.4820.86156.001,969,535.005.477.448.5712.0739.8242.2111.3415.102.79--0.191339.347.1810.15-11.594.55-8.303.37
Ocumension Therapeutics615.11m-281.98m5.71bn505.00--1.38--9.28-0.3764-0.37640.82145.080.15714.303.351,257,900.00-7.20-24.03-7.62-25.7142.5858.38-45.84-400.904.86--0.0223--69.38365.9529.36--213.01--
Beijing Tong Ren Tang Chinese Medicine1.71bn515.36m7.53bn789.0014.621.8712.004.410.61570.61572.044.810.38780.41344.922,185,246.0012.1415.3413.3417.1763.0068.9431.2939.1611.43--0.032752.525.692.38-7.42-2.0920.508.76
China Shineway Pharmaceutical Group Ltd3.78bn936.99m8.10bn2.87k7.890.916410.392.141.241.245.0110.680.32991.153.811,174,894.008.178.2910.7510.3873.3674.8324.7718.673.39--0.041937.49-16.356.90-13.3510.808.9219.39
CStone Pharmaceuticals229.08m-426.61m8.72bn93.00--22.63--38.08-0.3273-0.32730.17680.26120.14871.381.681,696,892.00-27.69-39.13-54.45-60.19-12.1866.69-186.23-170.861.20-29.830.554---12.21--75.16------
SSY Group Ltd4.58bn658.92m8.76bn5.70k13.541.237.791.910.2230.2231.552.460.36162.272.11751,065.605.279.416.3412.4342.6856.4714.5817.652.4014.910.34642.91-10.674.49-19.53-1.36-8.369.73
Hbm Holdings Ltd904.32m571.07m10.28bn210.0015.964.2517.1911.370.74050.74051.142.780.38566.3232.645,796,901.0024.77-42.8730.77-53.2492.9596.1264.25-292.586.0228.630.1857---57.4347.71-87.81---55.31--
China Traditional Chinese Med Hldg CoLtd17.63bn-299.61m10.32bn15.58k--0.440811.360.5854-0.0595-0.05953.504.650.43261.591.711,052,615.00-0.933.48-1.425.2447.6654.69-2.157.391.519.550.133321.27-8.902.89-95.79-49.14-15.28-48.82
Luye Pharma Group Ltd6.98bn449.06m10.79bn5.12k22.620.6116.741.550.11940.11941.864.420.20832.422.371,354,931.001.911.983.263.1666.8568.379.158.041.242.350.42270.00-1.33-0.9503-11.40-19.50-10.95--
Fujian Haixi Pharmaceuticals Co Ltd-100.00bn-100.00bn10.92bn--------------------------------------------------47.39--15.86------
Data as of Feb 16 2026. Currency figures normalised to SSY Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.16%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management (Europe) SAas of 05 Feb 202697.55m3.31%
UBS Switzerland AG (Investment Management)as of 05 Feb 202658.70m1.99%
The Vanguard Group, Inc.as of 04 Feb 202646.05m1.56%
Dimensional Fund Advisors LPas of 05 Feb 202636.07m1.22%
BlackRock Fund Advisorsas of 06 Feb 202619.79m0.67%
UBS Asset Management (Hong Kong) Ltd.as of 05 Feb 202619.02m0.64%
Norges Bank Investment Managementas of 30 Jun 202517.28m0.59%
Penghua Fund Management Co., Ltd.as of 30 Jun 202517.22m0.58%
Bosera Asset Management Co., Ltd.as of 30 Jun 20259.08m0.31%
American Century Investment Management, Inc.as of 05 Feb 20268.52m0.29%
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.